SYnabs & Biokit announce strategic collaboration on valproic acid antigen

SYnAbs & Biokit, A Werfen Company are proud to announce their success in the development of the best anti-valproic acid monoclonal antibody of the market! This case study is a new proof of the high efficiency of SYnAbs technologies for the generation of antibodies against haptens.

Exhibitor Data Sheet

.fairmate_js_notification_overlay { z-index: 9000; position: fixed; top: 0; bottom: 0; left: 0; right: 0; background-color: rgb(204, 204, 204); background-color: rgba(204, 204, 204, 0.7); } .fairmate_js_notification_popup_dlg { background-color: #fff !important; margin-left: auto; margin-right: auto; width: 570px; margin-top: 10%; } .fairmate_js_notification_popup_header { display: flex; justify-content: center; padding: 10px; } .fairmate_js_notification_popup_content { padding: 10px 60px 30px; } .fairmate_js_notification_popup_footer { display: flex; justify-content: center; padding-bottom: 30px; }

This page requires JavaScript

To use the full function of this web site, JavaScript needs to be enabled in your browser.

This is how you enable JavaScript in your browser settings:
Read instruction